Startup Scout 18 Oct 2019 This Biotech Fights Autoimmune Disease with Rare Immune Cells …approved to treat autoimmune conditions such as NSAIDs and steroids typically suppress the whole immune system, leaving patients susceptible to infections. “Those diseases are disabling diseases, with drugs that are… October 18, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Dec 2018 Looking Back on 2018: Our 10 Most Popular Interviews …target a wide arrange of rare genetic diseases, including several forms of blindness. 4. Bravo! An interview with the CEO of Takeda’s recent cell therapy target After beginning his career… December 24, 2018 - 8 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 9 Nov 2017 Meet the Spin-Out Queen Taking on Neurological Diseases Mary Kerr, CEO of NeRRe and Managing Director of KanDy, told us how its approaches could change the face of therapies for neuronal hypersensitivity and women’s health indications. Mary Kerr’s… November 9, 2017 - 4 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 4 Jan 2021 What Does the Next Decade Have in Store for European Biotech? …Bause, who leads a venture creation program at the investment firm Apollo Health Ventures. Gene therapy is most often associated with curing genetic diseases and treating cancer, but Bause sees… January 4, 2021 - 9 minutesmins - By Karen O’Hanlon Cohrt Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2022 Gate Neurosciences emerges from stealth to tackle CNS diseases Gate Neurosciences has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system (CNS) disorders. Gate Neurosciences, a U.S. biotech company, was founded… August 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 3 Mar 2021 The Promises of CRISPR Genome Editing in Biomedicine …can offer to medicine. For example, it’s critical to move the field beyond therapeutic areas of rare diseases and hematologic malignancies, and into common diseases, like cancer and diabetes, where… March 3, 2021 - 5 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2017 Belgian Biotech Launches IPO, Readying Itself to Fight Multiple Sclerosis …give it the power to tackle both well-known and neglected autoimmune diseases that are desperately suffering from an unmet medical need. Apitopes treat autoimmune diseases early on during the inflammation… November 1, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 5 May 2023 The biggest private biotech investments in April 2023 …B financing to support phase 1 and 2 trials of its human pluripotent stem cell candidates for lung diseases, degenerative joint diseases, central nervous system (CNS) diseases, and more. Other… May 5, 2023 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
More News! 19 Nov 2018 Anti-Inflammatory Treatments Get €40M Boost in Series B …factor for many diseases, such as neurodegenerative diseases, autoimmune conditions, and cancer, because it can damage tissue if uncontrolled. One particular inflammasome in Inflazome’s sights is NLRP3. “The NLRP3 inflammasome… November 19, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 21 Mar 2017 Rethinking Profits: Can a Socially Conscious Model work in Biotech? …applied to more common diseases. “Whatever we do here, we hope to apply the same tech to diseases that affect more people, like sickle cell anemia and cancer,” says Revah…. March 21, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2016 Meet the First Biotech to Jump on Autophagy After This Years’ Nobel Prize Just after the Nobel Prize was awarded to the study of autophagy, PhoreMost announces a collaboration to target the process in neurodegenerative diseases. PhoreMost is a drug discovery company that… October 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 Ascidian Therapeutics launches with $50M to rewrite RNA Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, has been launched. With an initial focus on replacing mutated exons at the RNA level, Ascidian’s technology… October 12, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email